(Q37930205)

25 August 2017

1 reference

title

The future of chronic obstructive pulmonary disease treatment--difficulties of and barriers to drug development (English)

1 reference

chronic obstructive pulmonary disease

25 August 2017

0 references

1

Fernando J Martinez

1 reference

25 August 2017

James F Donohue

2

1 reference

PubMed ID

21907866

25 August 2017

Stephen I Rennard

series ordinal

3

1 reference

PubMed ID

21907866

25 August 2017

language of work or name

English

0 references

publication date

1 September 2011

1 reference

25 August 2017

1 reference

25 August 2017

378

1 reference

25 August 2017

1027-1037

1 reference

25 August 2017

9795

1 reference

Global burden of COPD: systematic review and meta-analysis

25 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Projections of global mortality and burden of disease from 2002 to 2030

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Estimating the cost of new drug development: is it really 802 million dollars?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Emerging pharmacotherapies for COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

The natural history of chronic airflow obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Airflow obstruction attributable to work in industry and occupation among U.S. race/ethnic groups: a study of NHANES III data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

American Thoracic Society statement: occupational contribution to the burden of airway disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Small airways dimensions in asthma and in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

The nature of small-airway obstruction in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Chronic obstructive pulmonary disease phenotypes: the future of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

The many "small COPDs": COPD should be an orphan disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Pulmonary hypertension in chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Pulmonary vascular involvement in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Is alveolar destruction and emphysema in chronic obstructive pulmonary disease an immune disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Inhibition of VEGF receptors causes lung cell apoptosis and emphysema

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Ventilation-perfusion imbalance and chronic obstructive pulmonary disease staging severity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Circulating haemopoietic and endothelial progenitor cells are decreased in COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Identification of vascular progenitor cells in pulmonary arteries of patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

A human model of the pathophysiology of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Exacerbations of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

The biology of a chronic obstructive pulmonary disease exacerbation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

COPD exacerbations: defining their cause and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Prospects for new drugs for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

The cytokine network in asthma and chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Biologic and pharmacologic therapies in clinical development for the inflammatory response in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Changing pattern of sputum cell counts during successive exacerbations of airway disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

[COPD: bronchial and systemic inflammation]

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Toward therapeutic pulmonary alveolar regeneration in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Intranasal HGF administration ameliorates the physiologic and morphologic changes in lung emphysema.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Amelioration of pulmonary emphysema by in vivo gene transfection with hepatocyte growth factor in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Bone marrow-derived cells contribute to lung regeneration after elastase-induced pulmonary emphysema.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Palifermin induces alveolar maintenance programs in emphysematous mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Adrenomedullin regenerates alveoli and vasculature in elastase-induced pulmonary emphysema in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Adrenomedullin promotes lung angiogenesis, alveolar development, and repair

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Chronic Obstructive Pulmonary Disease Biomarker(s) for Disease Activity Needed—Urgently

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Design of a Clinical Trial to Test a Treatment of the Underlying Cause of Emphysema

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Systemic manifestations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

1 reference

7 January 2021

Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Definition of the phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Gender and chronic obstructive pulmonary disease: why it matters

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

The value of forced expiratory volume in 1 second decline in the assessment of chronic obstructive pulmonary disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Is the short-term response to inhaled beta-adrenergic agonist sensitive or specific for distinguishing between asthma and COPD?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Prevalence and clinical correlates of bronchoreversibility in severe emphysema

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Contribution of emphysema and small airways in COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

The diffusing capacity as a predictor of arterial oxygen desaturation during exercise in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Clinical significance of radiologic characterizations in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Quantitative computed tomography measures of emphysema and airway wall thickness are related to respiratory symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Airway dimensions in COPD: Relationships with clinical variables

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Predictors of mortality in patients with emphysema and severe airflow obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

CT scan findings of emphysema predict mortality in COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Systemic effects of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

The modified BODE index: validation with mortality in COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Development and Validation of a Prognostic Index for Health Outcomes in Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

The SAFE (SGRQ score, air-flow limitation and exercise tolerance) Index: a new composite score for the stratification of severity in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Distinct clinical phenotypes of airways disease defined by cluster analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Clinical COPD phenotypes: a novel approach using principal component and cluster analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Lung function impairment, COPD hospitalisations and subsequent mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Cluster analysis in severe emphysema subjects using phenotype and genotype data: an exploratory investigation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Patients at high risk of death after lung-volume-reduction surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Bronchodilation in COPD: beyond FEV1-the effect of albuterol on resistive and reactive properties of the respiratory system.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Improved respiratory system conductance following bronchodilator predicts reduced exertional dyspnoea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Development and first validation of the COPD Assessment Test.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Measuring functional performance in patients with COPD: a discussion of patient-reported outcome measures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Health status in COPD cannot be measured by the St George's Respiratory Questionnaire alone: an evaluation of the underlying concepts of this questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Toward a consensus definition for COPD exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Definitions of exacerbations: does it really matter in clinical trials on COPD?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Temporal Clustering of Exacerbations in Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Negative impacts of unreported COPD exacerbations on health-related quality of life at 1 year.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Characterizing and quantifying the symptomatic features of COPD exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Quantitative imaging of COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Diagnostic imaging in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Report of a workshop: quantitative computed tomography scanning in longitudinal studies of emphysema.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Detection of emphysema progression in alpha 1-antitrypsin deficiency using CT densitometry; methodological advances

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Therapeutic efficacy of α-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Quantitative computed tomography of lung parenchyma in chronic obstructive pulmonary disease: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Updating the minimal important difference for six-minute walk distance in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Interpretation of treatment changes in 6-minute walk distance in patients with COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Minimum clinically important improvement for the incremental shuttle walking test

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

Significance of changes in endurance shuttle walking performance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

How can we assess outcomes of clinical trials: the MCID approach

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

The FDA and safe use of long-acting beta-agonists in the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961047-7

7 January 2021

10.1016/S0140-6736(11)61047-7

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21907866